Abstract
Background The coronavirus 2019 (COVID-19) pandemic has been spreading globally for months, yet the infection fatality ratio of the disease is still uncertain. This is partly because of inconsistencies in testing and death reporting standards across countries. We provide estimates which don’t rely on official cases and deaths data but only on population level statistics.
Methods We collected demographic and death records data from the Italian Institute of Statistics. We focus on the area in Italy that experienced the initial outbreak of COVID-19 and estimated a Bayesian model fitting age-stratified mortality data from 2020 and previous years. We also assessed the sensitivity of our results to alternative assumptions on the proportion of population infected. Based on our estimates we finally studied the heterogeneity in overall lethality across countries.
Findings We estimate an overall infection fatality rate of 1.31% (95% credible interval [CrI] 0.94 – 1.89), as well as large differences by age, with a low infection fatality rate of 0.05% for under 60 year old (CrI 0 – 0.17) and a substantially higher 4.16% (CrI 3.05 – 5.80) for people above 60 years of age. In our sensitivity analysis, we found that even under extreme assumptions, our method delivered useful information. For instance, even if only 10% of the population were infected, the infection fatality rate would not rise above 0.2% for people under 60. Finally, using data on demographics we show large expected heterogeneity in overall IFR across countries.
Interpretation Our empirical estimates show a sharp difference in fatality rates between young and old people and rule out overall fatality ratios below 0.5% in populations with more than 30% over 60 years old.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all data in the study and had final responsibility for the decision to submit for publication.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is publicly available and can be found at the cited sources.
